Congratulations to the two nephrology trials selected for funding by the Accelerating Clinical Trials (ACT) Consortium!
The objective of this request for applications was to fund partnerships with Canadian-controlled biotechnology companies and ACT/AEC Network clinical trialists. The consortium received 30 applications and selected 6 projects for funding up to $400,000 each.
Each proposal underwent a targeted peer review process where each application was reviewed by a total of 10 independent reviewers – 5 reviewers with experience in clinical trials and 5 reviewers with experience in biotechnology.
We are proud to announce that 2 of the 6 projects selected were endorsed by CNTN.
Biotech: Arch Biopartners Inc.
You can see the full list of awarded trials here
The ACT Consortium was established to advance and facilitate the implementation of high-quality, high-impact randomized controlled trials (RCTs) to improve global health. For more information on the consortium, visit www.act-aec.com.